Public comment period · §3
Draft synthesis: Tirzepatide compared with semaglutide in… — disposition
The disposition of every submission and the amendments that resulted.
§3Disposition and amendments
§3.1Disposition table
Table 1. Every submission with its disposition. Each row links to the submission in full.
| Reference | Respondent | Point raised | Disposition |
|---|---|---|---|
| DRAFT-TIRZEPATIDE-/004 | Dr Oswin Yorkstone | The search strategy as published cannot be re-run | Accepted |
| DRAFT-TIRZEPATIDE-/003 | Dr Kamila Ubertini | Subgroup findings are reported that were not registered in the protocol | Accepted in part |
| DRAFT-TIRZEPATIDE-/006 | Dr Quintus Kettlewell | The review question is drawn too broadly to be answerable | Not accepted |
| DRAFT-TIRZEPATIDE-/007 | Dr Ottoline Oppenheimer-Ade | A sortable table implies a comparison the underlying data do not support | Noted, no amendment |
| DRAFT-TIRZEPATIDE-/005 | Dr Theodora Ingelbrecht | Point estimates are given without an interval | Accepted in part |
| DRAFT-TIRZEPATIDE-/001 | Dr Quentin Whitmarsh-Obi | A superseded version should remain reachable from the version that replaced it | Noted, no amendment |
| DRAFT-TIRZEPATIDE-/002 | Dr Delphine Trelawney | Studies using different outcome definitions are pooled into one estimate | Accepted |
| 7 submissions in total. | |||
§3.2Summary by disposition
Table 2. Counts by disposition, with the meaning of each.
| Disposition | Count | Meaning |
|---|---|---|
| Accepted | 2 | The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission. |
| Accepted in part | 2 | Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined. |
| Noted, no amendment | 2 | The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response. |
| Not accepted | 1 | The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it. |
§3.3Resulting amendments
- The search strategy as published cannot be re-run — arising from DRAFT-TIRZEPATIDE-/004. The full line-by-line strategy for each database is now published with the interface, the run date and the yield at each line, and the total retrieved is reconciled against the screening flow.
- Subgroup findings are reported that were not registered in the protocol — arising from DRAFT-TIRZEPATIDE-/003. Every subgroup analysis is now labelled as pre-specified or post hoc against the registered protocol, post hoc analyses are reported in a separate subsection without a certainty rating, and the protocol version against which the labelling was made is stated.
- Point estimates are given without an interval — arising from DRAFT-TIRZEPATIDE-/005. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
- Studies using different outcome definitions are pooled into one estimate — arising from DRAFT-TIRZEPATIDE-/002. Studies are now pooled only within an outcome definition, each definition is reported with its own estimate and certainty rating, and the summary of findings states which definition each row concerns.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-CP-118/3 · https://compoundevidence.com/comment-periods/draft-tirzepatide-vs-semaglutide-t2d-synthesis/disposition/ · retrieved 30 July 2026